Letter to the Editor: Reassessing intravenous antihypertensive choice in coronary artery disease-related hypertensive emergencies
World Journal of Cardiology · 26.07.2026 · 18 (7)
DOI: 10.4330/wjc.118635 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Cardiology, online erschienen am 26.07.2026. Verfasst von Nikolaos Ktenopoulos und 5 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Hypertensive emergencies in patients with established coronary artery disease (CAD) present a therapeutic paradox, that blood pressure must be lowered rapidly to limit end-organ damage, yet excessive or poorly selected pharmacologic intervention risks myocardial ischemia and adverse cardiovascular outcomes. In this context, a study by Chaudhary et al , published in the recent issue of the World Journal of Cardiology , provide novel and clinically interesting real-world data comparing intravenous nitroglycerin and labetalol in a large retrospective cohort of CAD patients presenting with hypertensive emergency. Their analysis demonstrates a nuanced trade-off between hemodynamic speed and cardioprotective benefit. While labetalol achieved target blood pressure more rapidly, nitroglycerin was associated with greater absolute blood pressure reduction, fewer bradyarrhythmic events, attenuated cardiac biomarker elevation, shorter intensive care unit and hospital stays, and lower 30-day readmission rates. Although major adverse cardiovascular events did not differ significantly, the observed trends favoring nitroglycerin underscore the importance of ischemia-sensitive blood pressure management in this high-risk population. Importantly, these findings align with the contemporary guideline principles that prioritize myocardial perfusion and preload reduction in CAD-associated hypertensive crises. Despite the inherent limitations of the retrospective, single-center analyses, this study advances the evidence base by focusing specifically on CAD patients in a resource-constrained setting and by incorporating clinically meaningful utilization outcomes. Collectively, the data support a more deliberate, phenotype-driven approach to agent selection in hypertensive emergencies, positioning nitroglycerin as a preferential option when myocardial ischemia is a central concern, while reinforcing the need for prospective, randomized validation.
Zitieren
APA
Ktenopoulos, N., Milaras, N., Apostolos, A., Tsioufis, K., Toutouzas, K., & Sideris, S. (2026). Letter to the Editor: Reassessing intravenous antihypertensive choice in coronary artery disease-related hypertensive emergencies. World Journal of Cardiology, 18(7). https://doi.org/10.4330/wjc.118635
Vancouver
Ktenopoulos N, Milaras N, Apostolos A, Tsioufis K, Toutouzas K, Sideris S. Letter to the Editor: Reassessing intravenous antihypertensive choice in coronary artery disease-related hypertensive emergencies. World Journal of Cardiology. 2026;18(7). doi:10.4330/wjc.118635
BibTeX
@article{Ktenopoulos2026,
author = {Ktenopoulos, Nikolaos and Milaras, Nikias and Apostolos, Anastasios and Tsioufis, Konstantinos and Toutouzas, Konstantinos and Sideris, Skevos},
title = {Letter to the Editor: Reassessing intravenous antihypertensive choice in coronary artery disease-related hypertensive emergencies},
journal = {World Journal of Cardiology},
year = {2026},
volume = {18},
number = {7},
doi = {10.4330/wjc.118635}
}
EUVIMED